Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Abstract Objectives With the improved prognosis of patients with biliary tract cancer (BTC) owing to advances in chemotherapy, long‐term stent patency has become an important goal in patients undergoing biliary stent placement. We compared the duration of stent patency between unresectable BTC patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Shunsuke Imamura, Kazuo Watanabe, Kanae Inoue, Tomonao Taira, Taro Shibuki, Tomoyuki Satake, Shota Yamaguchi, Mitsuhito Sasaki, Hiroshi Imaoka, Shuichi Mitsunaga, Masafumi Ikeda
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:DEN Open
Subjects:
Online Access:https://doi.org/10.1002/deo2.70075
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849714744006541312
author Shunsuke Imamura
Kazuo Watanabe
Kanae Inoue
Tomonao Taira
Taro Shibuki
Tomoyuki Satake
Shota Yamaguchi
Mitsuhito Sasaki
Hiroshi Imaoka
Shuichi Mitsunaga
Masafumi Ikeda
author_facet Shunsuke Imamura
Kazuo Watanabe
Kanae Inoue
Tomonao Taira
Taro Shibuki
Tomoyuki Satake
Shota Yamaguchi
Mitsuhito Sasaki
Hiroshi Imaoka
Shuichi Mitsunaga
Masafumi Ikeda
author_sort Shunsuke Imamura
collection DOAJ
description Abstract Objectives With the improved prognosis of patients with biliary tract cancer (BTC) owing to advances in chemotherapy, long‐term stent patency has become an important goal in patients undergoing biliary stent placement. We compared the duration of stent patency between unresectable BTC patients undergoing multi‐stenting for malignant hilar biliary obstruction by the side‐by‐side (SBS) and stent‐in‐stent (SIS) techniques during systemic chemotherapy. Methods We retrospectively evaluated the data of 62 unresectable BTC patients who underwent multi‐stenting before the first or second cycle of first‐line chemotherapy. Stent deployment was performed by the SBS technique in 40 patients (SBS group) and by the SIS technique in 22 patients (SIS group). Results The median time‐to‐recurrent biliary obstruction was 147 days in the SBS group and 252 days in the SIS (p = 0.029), being longer in the SIS group. The rates of development of early adverse events were 28% and 9% (p = 0.09) and the rates of development of late adverse events were 26% and 14% in the SBS and SIS groups (p = 0.27). The median overall survival was 480 days in the SBS group and 563 days in the SIS group (p = 0.92). Conclusion The duration of stent patency was shorter in the SBS group than in the SIS group; thus, the SIS technique is preferable to the SBS technique for biliary stent deployment in unresectable BTC patients during systemic chemotherapy.
format Article
id doaj-art-9aeb3ce7ea5b4ae091c0de544dbef09c
institution DOAJ
issn 2692-4609
language English
publishDate 2025-04-01
publisher Wiley
record_format Article
series DEN Open
spelling doaj-art-9aeb3ce7ea5b4ae091c0de544dbef09c2025-08-20T03:13:36ZengWileyDEN Open2692-46092025-04-0151n/an/a10.1002/deo2.70075Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstructionShunsuke Imamura0Kazuo Watanabe1Kanae Inoue2Tomonao Taira3Taro Shibuki4Tomoyuki Satake5Shota Yamaguchi6Mitsuhito Sasaki7Hiroshi Imaoka8Shuichi Mitsunaga9Masafumi Ikeda10Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanDepartment of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba JapanAbstract Objectives With the improved prognosis of patients with biliary tract cancer (BTC) owing to advances in chemotherapy, long‐term stent patency has become an important goal in patients undergoing biliary stent placement. We compared the duration of stent patency between unresectable BTC patients undergoing multi‐stenting for malignant hilar biliary obstruction by the side‐by‐side (SBS) and stent‐in‐stent (SIS) techniques during systemic chemotherapy. Methods We retrospectively evaluated the data of 62 unresectable BTC patients who underwent multi‐stenting before the first or second cycle of first‐line chemotherapy. Stent deployment was performed by the SBS technique in 40 patients (SBS group) and by the SIS technique in 22 patients (SIS group). Results The median time‐to‐recurrent biliary obstruction was 147 days in the SBS group and 252 days in the SIS (p = 0.029), being longer in the SIS group. The rates of development of early adverse events were 28% and 9% (p = 0.09) and the rates of development of late adverse events were 26% and 14% in the SBS and SIS groups (p = 0.27). The median overall survival was 480 days in the SBS group and 563 days in the SIS group (p = 0.92). Conclusion The duration of stent patency was shorter in the SBS group than in the SIS group; thus, the SIS technique is preferable to the SBS technique for biliary stent deployment in unresectable BTC patients during systemic chemotherapy.https://doi.org/10.1002/deo2.70075biliary tract cancerchemotherapymalignant hilar biliary obstructionside‐by‐sidestent‐in‐stent
spellingShingle Shunsuke Imamura
Kazuo Watanabe
Kanae Inoue
Tomonao Taira
Taro Shibuki
Tomoyuki Satake
Shota Yamaguchi
Mitsuhito Sasaki
Hiroshi Imaoka
Shuichi Mitsunaga
Masafumi Ikeda
Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
DEN Open
biliary tract cancer
chemotherapy
malignant hilar biliary obstruction
side‐by‐side
stent‐in‐stent
title Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
title_full Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
title_fullStr Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
title_full_unstemmed Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
title_short Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
title_sort side by side versus stent in stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
topic biliary tract cancer
chemotherapy
malignant hilar biliary obstruction
side‐by‐side
stent‐in‐stent
url https://doi.org/10.1002/deo2.70075
work_keys_str_mv AT shunsukeimamura sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT kazuowatanabe sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT kanaeinoue sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT tomonaotaira sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT taroshibuki sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT tomoyukisatake sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT shotayamaguchi sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT mitsuhitosasaki sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT hiroshiimaoka sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT shuichimitsunaga sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction
AT masafumiikeda sidebysideversusstentinstenttechniqueforstentdeploymentduringsystemicchemotherapyinbiliarytractcancerpatientswithmalignanthilarbiliaryobstruction